Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.

Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, Melenhorst JJ, Lacey SF, Xu X, Wherry EJ, Gangadhar TC, Amaravadi RK, Schuchter LM, Vonderheide RH.

Oncoimmunology. 2018 Aug 20;7(10):e1468956. doi: 10.1080/2162402X.2018.1468956. eCollection 2018.

2.

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen.

Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, Byrne KT, Stanger BZ, Riley JL, Markosyan N, Winograd R, Vonderheide RH.

JCI Insight. 2016 Sep 8;1(14). pii: 88328. doi: 10.1172/jci.insight.88328.

3.

Metastatic progression is associated with dynamic changes in the local microenvironment.

Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, Cornish TC, Iacobuzio-Donahue CA, Vonderheide RH, Stanger BZ.

Nat Commun. 2016 Sep 15;7:12819. doi: 10.1038/ncomms12819.

4.

CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.

Byrne KT, Leisenring NH, Bajor DL, Vonderheide RH.

J Immunol. 2016 Jul 1;197(1):179-87. doi: 10.4049/jimmunol.1600146. Epub 2016 May 23.

5.

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH.

Cancer Immunol Res. 2015 Apr;3(4):399-411. doi: 10.1158/2326-6066.CIR-14-0215. Epub 2015 Feb 12.

6.

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH.

Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.

7.

Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer.

Bajor DL, Vonderheide RH.

J Immunother. 2013 Sep;36(7):362-4. doi: 10.1097/CJI.0b013e31829fb7c8. No abstract available.

PMID:
23924787
8.

CD40 immunotherapy for pancreatic cancer.

Vonderheide RH, Bajor DL, Winograd R, Evans RA, Bayne LJ, Beatty GL.

Cancer Immunol Immunother. 2013 May;62(5):949-54. doi: 10.1007/s00262-013-1427-5. Epub 2013 Apr 16. Review.

9.

Rehabilitation for oncogene addiction: role of immunity in cellular sobriety.

Bajor DL, Vonderheide RH.

Clin Cancer Res. 2012 Mar 1;18(5):1192-4. doi: 10.1158/1078-0432.CCR-11-3322. Epub 2012 Jan 20.

10.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.

J Clin Oncol. 2007 Mar 1;25(7):876-83.

PMID:
17327609
11.

High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.

Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.

Biol Blood Marrow Transplant. 2005 Jan;11(1):13-22.

Supplemental Content

Loading ...
Support Center